Printer Friendly

AnaSpec Launches the EnzoLyte(TM) 520 Renin Assay Kit with Ultra-High Sensitivity.

SAN JOSE, Calif. -- The past decade has witnessed the development of a number of synthetic renin inhibitors1-3. However, increasing demand for accelerated drug discovery and automated inhibitor screening has generated a need for a continuous, homogeneous assay with even greater sensitivity. With the introduction of the ultra-sensitive EnzoLyte(TM )520 Renin Assay Kit, AnaSpec now offers a renin assay kit that is 40x more sensitive than comparable kits currently in the market.

Renin, a highly specific aspartyl protease, cleaves angiotensinogen, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin Converting Enzyme). Angiotensin II constricts blood vessels, leading to increased blood pressure. Angiotensin II also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex. Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease.

While existing renin assay kits offer sub-nanomolar potency and selectivity, AnaSpec's EnzoLyte(TM) 520 Renin Assay Kit offers picomolar sensitivity - the highest sensitivity available for commercial renin assay kits.

AnaSpec also offers a shorter emission wavelength kit, EnzoLyte[TM] 390 Renin Assay Kit - a cost-effective option that offers greater sensitivity than EDANS/DABCYL-based renin assay kits.

EnzoLyte[TM] 520 Renin Assay Kit (http://www.anaspec.com/products/product.asp?id=33273)

EnzoLyte[TM] 390 Renin Assay Kit (http://www.anaspec.com/products/product.asp?id=33272)
[TABLE OMITTED]


For more information, visit www.anaspec.com

AnaSpec, Inc., located in San Jose, CA, is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development.

Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA. AnaSpec maintains ISO9001 certification, holds a California Drug Manufacturing License and a FDA Registration for GMP Drug Manufacturing.

References:

1. Wood, JM. et al., Hypertension, 7, 797 (1985).

2. Shibasaki, M. et al., Am. J. Hypertens. 4, 932 (1991).

3. Wood, JM. et al., Biochem. Biophys. Res. Comm. 308, 698 (2003).
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 9, 2007
Words:381
Previous Article:Apria Announces Fourth Quarter 2006 Earnings Conference Call.
Next Article:Intelsat Announces Pricing of Notes.
Topics:


Related Articles
Renovascular Hypertension: Can We Identify a Population at High Risk? (Featured CME Topic: Hypertension).
SARS coronavirus detection.
PathAlert Infectious-Agent Detection System.
Vitamin D deficiency in primary aldosteronism*.
DXS LAUNCHES LATEST GENE MUTATION TEST KIT.
Primary aldosteronism and secondary hyperparathyroidism of the vitamin D deficiency.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters